Dividend Policy
ASKA Pharmaceutical Holdings regards the return of profits to shareholders as one of the most important management issues. The Company's policy is to return profits to shareholders in an appropriate manner in line with business performance, while adhering to the conventional approach of managing the Company with an awareness of the cost of capital and its share price. Starting from FY2024, the Company will maintain stable profit distribution by indicating a consolidated dividend payout ratio of 30% as performance-linked profit distribution, with a minimum annual dividend per share of 30 yen.
The Company's basic policy is to pay dividends from surplus twice a year, an interim dividend and a year-end dividend. The decision-making bodies for these dividends are the General Meeting of Shareholders for the year-end dividend and the Board of Directors for the interim dividend.
Retained earnings will be utilized to further increase earnings and strengthen the corporate structure through investments in R&D and production facilities.
Dividends in the Current and the Following Period
(As of November 6, 2023)
Based on the above considerations, and reflecting recent trends in business performance, we have paid year-end dividends of 8 yen per share, combined with the interim dividends of 8 yen per share already paid. As a result, the annual dividend was 16 yen per share.
For FY2023, the Company plans to pay an annual dividend of 40 yen per share (20 yen interim dividend and 20 yen year-end dividend), which is higher than the previous fiscal year, taking into account the solid performance and the extraordinary gain from the sale of investment securities.